MAIA's Phase 3 NSCLC Trial Reaches 65 Patients Amid Encouraging DCR Data

What happened

MAIA Biotechnology announced enrollment of 65 patients in its pivotal Phase 3 THIO-104 trial for third-line advanced NSCLC. The company also cited a most recent assessment showing 90.5% disease control rate for its telomere-targeting agent sequenced with a checkpoint inhibitor in heavily pretreated patients. This update follows prior Phase 2 data suggesting a median overall survival of 16.9 months in a small cohort. However, the master report highlights that MAIA remains pre-revenue with substantial going-concern warnings and only about $10 million in cash as of mid-2025. The enrollment pace is a positive execution signal, but it does not yet alleviate the financing and clinical execution risks that underpin the current WAIT stance.

Implication

The 65-patient enrollment milestone demonstrates operational progress on the Phase 3 program, which is critical to validating THIO in a registrational setting. The 90.5% DCR, if from the ongoing Phase 2, reinforces the early efficacy signal but remains from a small, uncontrolled study with inherent selection bias. Financing remains the primary near-term risk: with cash of roughly $10 million and a planned Phase 3 of up to 300 patients, significant dilution or a strategic partnership is likely necessary. The high bar set by recent approvals and failures in post-checkpoint NSCLC means only mature, robust Phase 3 data can materially de-risk the story. Investors should monitor financing announcements, enrollment pace relative to projections, and any interim efficacy or safety updates from THIO-101 and THIO-104.

Thesis delta

The news does not materially alter the investment thesis beyond confirming enrollment execution. The WAIT judgment from the master report remains appropriate, as the fundamental risks of going concern and unproven registrational efficacy persist. A shift to a more constructive stance would require resolution of funding runway or compelling Phase 3 interim data.